Fibronectin splice variants: Understanding their multiple roles in health and disease using engineered mouse models
dc.contributor.author | Ovádi, Judit | en_US |
dc.date.accessioned | 2011-11-10T15:35:31Z | |
dc.date.available | 2012-09-04T15:27:43Z | en_US |
dc.date.issued | 2011-07 | en_US |
dc.identifier.citation | Ovádi, Judit (2011). "Fibronectin splice variants: Understanding their multiple roles in health and disease using engineered mouse models." IUBMB Life 63(7): 538-546. <http://hdl.handle.net/2027.42/86988> | en_US |
dc.identifier.issn | 1521-6543 | en_US |
dc.identifier.issn | 1521-6551 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/86988 | |
dc.description.abstract | The extracellular matrix (ECM) is a highly dynamic network of proteins, glycoproteins, and proteoglycans. Numerous diseases result from mutation in genes coding for ECM proteins, but only recently it has been reported that mutations in the fibronectin (FN) gene were associated with a human disorder. FN is one of the main components of the ECM. It generates protein diversity through alternative splicing of a single pre‐mRNA, having at least 20 different isoforms in humans. The precise function of these protein isoforms has remained obscure in most cases. Only in the recent few years, it was possible to shed light on the multiple roles of the alternatively spliced FN isoforms. This substantial progress was achieved basically with the knowledge derived from engineered mouse models bearing subtle mutations in specific FN domains. These data, together with a recent report associating mutations in the FN gene to a form of glomerulopathy, clearly show that mutations in constitutive exons or misregulation of alternatively spliced domains of the FN gene may have nonlethal pathological consequences. In this review, we focus on the pathological consequences of mutations in the FN gene, by connecting the function of alternatively spliced isoforms of fibronectin to human diseases. © 2011 IUBMB IUBMB Life, 63(7): 538–546, 2011 | en_US |
dc.publisher | Wiley Subscription Services, Inc., a Wiley company | en_US |
dc.subject.other | Disease Models | en_US |
dc.subject.other | Genetic Models | en_US |
dc.subject.other | Alternative Splicing | en_US |
dc.subject.other | Protein Function | en_US |
dc.subject.other | Complex Diseases | en_US |
dc.title | Fibronectin splice variants: Understanding their multiple roles in health and disease using engineered mouse models | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Ecology and Evolutionary Biology | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Mouse Molecular Genetics Laboratory, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy | en_US |
dc.contributor.affiliationother | International Centre for Genetic Engineering and Biotechnology, Padriciano 99, I‐34149 Trieste, Italy | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/86988/1/493_ftp.pdf | |
dc.identifier.doi | 10.1002/iub.493 | en_US |
dc.identifier.source | IUBMB Life | en_US |
dc.identifier.citedreference | Discher, D. E., Mooney, D. J., and Zandstra, P. W. ( 2009 ) Growth factors, matrices, and forces combine and control stem cells. Science 324, 1673 – 1677. | en_US |
dc.identifier.citedreference | Geiger, B., Spatz, J. P., and Bershadsky, A. D. ( 2009 ) Environmental sensing through focal adhesions. Nat. Rev. Mol. Cell Biol. 10, 21 – 33. | en_US |
dc.identifier.citedreference | Bateman, J. F., Boot‐Handford, R. P., and Lamande, S. R. ( 2009 ) Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations. Nat. Rev. Genet. 10, 173 – 183. | en_US |
dc.identifier.citedreference | Castelletti, F., Donadelli, R., Banterla, F., Hildebrandt, F., Zipfel, P. F., et al. ( 2008 ) Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc. Natl. Acad. Sci. USA 105, 2538 – 2543. | en_US |
dc.identifier.citedreference | Astrof, S., Crowley, D., and Hynes, R. O. ( 2007 ) Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectin. Dev. Biol. 311, 11 – 24. | en_US |
dc.identifier.citedreference | Fukuda, T., Yoshida, N., Kataoka, Y., Manabe, R., Mizuno‐Horikawa, Y., et al. ( 2002 ) Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res. 62, 5603 – 5610. | en_US |
dc.identifier.citedreference | George, E. L., Georges‐Labouesse, E. N., Patel‐King, R. S., Rayburn, H., and Hynes, R. O. ( 1993 ) Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119, 1079 – 1091. | en_US |
dc.identifier.citedreference | Georges‐Labouesse, E. N., George, E. L., Rayburn, H., and Hynes, R. O. ( 1996 ) Mesodermal development in mouse embryos mutant for fibronectin. Dev. Dyn. 207, 145 – 156. | en_US |
dc.identifier.citedreference | Muro, A. F., Chauhan, A. K., Gajovic, S., Iaconcig, A., Porro, F., et al. ( 2003 ) Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. J. Cell Biol. 162, 149 – 160. | en_US |
dc.identifier.citedreference | Sakai, T., Johnson, K. J., Murozono, M., Sakai, K., Magnuson, M. A., et al. ( 2001 ) Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin‐wound healing and hemostasis. Nat. Med. 7, 324 – 330. | en_US |
dc.identifier.citedreference | Takahashi, M., Saito, H., Higashimoto, M., and Hibi, T. ( 2007 ) Possible inhibitory effect of oral zinc supplementation on hepatic fibrosis through downregulation of TIMP‐1: a pilot study. Hepatol. Res. 37, 405 – 409. | en_US |
dc.identifier.citedreference | Tan, M. H., Sun, Z., Opitz, S. L., Schmidt, T. E., Peters, J. H., et al. ( 2004 ) Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood 104, 11 – 18. | en_US |
dc.identifier.citedreference | Hynes, R. O. ( 1990 ) Fibronectins. Springer‐Verlag, New York. | en_US |
dc.identifier.citedreference | White, E. S., Baralle, F. E., and Muro, A. F. ( 2008 ) New insights into form and function of fibronectin splice variants. J. Pathol. 216, 1 – 14. | en_US |
dc.identifier.citedreference | Gilbert, W. ( 1978 ) Why genes in pieces? Nature 271, 501. | en_US |
dc.identifier.citedreference | Hynes, R. O. ( 2007 ) Cell–matrix adhesion in vascular development. J. Thromb. Haemost. 5 ( Suppl 1 ), 32 – 40. | en_US |
dc.identifier.citedreference | Chauhan, A. K., Iaconcig, A., Baralle, F. E., and Muro, A. F. ( 2004 ) Alternative splicing of fibronectin: a mouse model demonstrates the identity of in vitro and in vivo systems and the processing autonomy of regulated exons in adult mice. Gene 324, 55 – 63. | en_US |
dc.identifier.citedreference | Peters, J. H. and Hynes, R. O. ( 1996 ) Fibronectin isoform distribution in the mouse. I. The alternatively spliced EIIIB, EIIIA, and V segments show widespread codistribution in the developing mouse embryo. Cell Adhes. Commun. 4, 103 – 125. | en_US |
dc.identifier.citedreference | Magnuson, V. L., Young, M., Schattenberg, D. G., Mancini, M. A., Chen, D. L., et al. ( 1991 ) The alternative splicing of fibronectin pre‐mRNA is altered during aging and in response to growth factors. J. Biol. Chem. 266, 14654 – 14662. | en_US |
dc.identifier.citedreference | Pagani, F., Zagato, L., Vergani, C., Casari, G., Sidoli, A., and Baralle, F. E. ( 1991 ) Tissue‐specific splicing pattern of fibronectin messenger RNA precursor during development and aging in rat. J. Cell Biol. 113, 1223 – 1229. | en_US |
dc.identifier.citedreference | Moretti, F. A., Chauhan, A. K., Iaconcig, A., Porro, F., Baralle, F. E., and Muro, A. F. ( 2007 ) A major fraction of fibronectin present in the extracellular matrix of tissues is plasma‐derived. J. Biol. Chem. 282, 28057 – 28062. | en_US |
dc.identifier.citedreference | Ffrench‐Constant, C., Van de Water, L., Dvorak, H. F., and Hynes, R. O. ( 1989 ) Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J. Cell Biol. 109, 903 – 914. | en_US |
dc.identifier.citedreference | Peters, J. H., Chen, G. E., and Hynes, R. O. ( 1996 ) Fibronectin isoform distribution in the mouse. II. Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments in the adult mouse. Cell Adhes. Commun. 4, 127 – 148. | en_US |
dc.identifier.citedreference | Carnemolla, B., Balza, E., Siri, A., Zardi, L., Nicotra, M. R., et al. ( 1989 ) A tumor‐associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell Biol. 108, 1139 – 1148. | en_US |
dc.identifier.citedreference | Rybak, J. N., Roesli, C., Kaspar, M., Villa, A., and Neri, D. ( 2007 ) The extra‐domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res. 67, 10948 – 10957. | en_US |
dc.identifier.citedreference | Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., et al. ( 1994 ) The fibronectin isoform containing the ED‐B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59, 612 – 618. | en_US |
dc.identifier.citedreference | Astrof, S., Crowley, D., George, E. L., Fukuda, T., Sekiguchi, K., et al. ( 2004 ) Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. Mol. Cell. Biol. 24, 8662 – 8670. | en_US |
dc.identifier.citedreference | Astrof, S. and Hynes, R. O. ( 2009 ) Fibronectins in vascular morphogenesis. Angiogenesis 12, 165 – 175. | en_US |
dc.identifier.citedreference | Bazigou, E., Xie, S., Chen, C., Weston, A., Miura, N., et al. ( 2009 ) Integrin‐alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. Dev. Cell 17, 175 – 186. | en_US |
dc.identifier.citedreference | Huang, X. Z., Wu, J. F., Ferrando, R., Lee, J. H., Wang, Y. L., et al. ( 2000 ) Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol. Cell. Biol. 20, 5208 – 5215. | en_US |
dc.identifier.citedreference | Paloschi, V., Kurtovic, S., Folkersen, L., Gomez, D., Wagsater, D., et al. ( 2011 ) Impaired splicing of fibronectin is associated with thoracic aortic aneurysm formation in patients with bicuspid aortic valve. Arterioscler. Thromb. Vasc. Biol. 31, 691 – 697. | en_US |
dc.identifier.citedreference | Babaev, V. R., Porro, F., Linton, M. F., Fazio, S., Baralle, F. E., and Muro, A. F. ( 2008 ) Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. Atherosclerosis 197, 534 – 540. | en_US |
dc.identifier.citedreference | Hernnas, J., Nettelbladt, O., Bjermer, L., Sarnstrand, B., Malmstrom, A., and Hallgren, R. ( 1992 ) Alveolar accumulation of fibronectin and hyaluronan precedes bleomycin‐induced pulmonary fibrosis in the rat. Eur. Respir. J. 5, 404 – 410. | en_US |
dc.identifier.citedreference | Muro, A. F., Moretti, F. A., Moore, B. B., Yan, M., Atrasz, R. G., et al. ( 2008 ) An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 177, 638 – 645. | en_US |
dc.identifier.citedreference | Jarnagin, W. R., Rockey, D. C., Koteliansky, V. E., Wang, S. S., and Bissell, D. M. ( 1994 ) Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J. Cell Biol. 127, 2037 – 2048. | en_US |
dc.identifier.citedreference | Serini, G., Bochaton‐Piallat, M. L., Ropraz, P., Geinoz, A., Borsi, L., et al. ( 1998 ) The fibronectin domain ED‐A is crucial for myofibroblastic phenotype induction by transforming growth factor‐beta1. J. Cell Biol. 142, 873 – 881. | en_US |
dc.identifier.citedreference | Kohan, M., Muro, A. F., Bader, R., and Berkman, N. ( 2011 ) The extra domain A of fibronectin is essential for allergen‐induced airway fibrosis and hyperresponsiveness in mice. J. Allergy Clin. Immunol. 127, 439 – 446 e431 – 435. | en_US |
dc.identifier.citedreference | Arslan, F., Smeets, M. B., Riem Vis, P. W., Karper, J. C., Quax, P. H., et al. ( 2011 ) Lack of Fibronectin‐EDA Promotes Survival and Prevents Adverse Remodeling and Heart Function Deterioration After Myocardial Infarction. Circ. Res. 108, 582 – 592. | en_US |
dc.identifier.citedreference | Balza, E., Borsi, L., Allemanni, G., and Zardi, L. ( 1988 ) Transforming growth factor beta regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS Lett. 228, 42 – 44. | en_US |
dc.identifier.citedreference | Murphy‐Ullrich, J. E. and Poczatek, M. ( 2000 ) Activation of latent TGF‐beta by thrombospondin‐1: mechanisms and physiology. Cytokine Growth Factor Rev. 11, 59 – 69. | en_US |
dc.identifier.citedreference | Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J., Dalton, S. L., et al. ( 1999 ) The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319 – 328. | en_US |
dc.identifier.citedreference | Blakytny, R., Ludlow, A., Martin, G. E., Ireland, G., Lund, L. R., et al. ( 2004 ) Latent TGF‐beta1 activation by platelets. J. Cell. Physiol. 199, 67 – 76. | en_US |
dc.identifier.citedreference | Fontana, L., Chen, Y., Prijatelj, P., Sakai, T., Fassler, R., et al. ( 2005 ) Fibronectin is required for integrin alphavbeta6‐mediated activation of latent TGF‐beta complexes containing LTBP‐1. FASEB J. 19, 1798 – 1808. | en_US |
dc.identifier.citedreference | Peters, J. H., Maunder, R. J., Woolf, A. D., Cochrane, C. G., and Ginsberg, M. H. ( 1989 ) Elevated plasma levels of ED1+ (“cellular”) fibronectin in patients with vascular injury. J. Lab. Clin. Med. 113, 586 – 597. | en_US |
dc.identifier.citedreference | Cho, J. and Mosher, D. F. ( 2006 ) Enhancement of thrombogenesis by plasma fibronectin cross‐linked to fibrin and assembled in platelet thrombi. Blood 107, 3555 – 3563. | en_US |
dc.identifier.citedreference | Ni, H., Papalia, J. M., Degen, J. L., and Wagner, D. D. ( 2003 ) Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood 102, 3609 – 3614. | en_US |
dc.identifier.citedreference | Matuskova, J., Chauhan, A. K., Cambien, B., Astrof, S., Dole, V. S., et al. ( 2006 ) Decreased plasma fibronectin leads to delayed thrombus growth in injured arterioles. Arterioscler. Thromb. Vasc. Biol. 26, 1391 – 1396. | en_US |
dc.identifier.citedreference | Castellanos, M., Leira, R., Serena, J., Blanco, M., Pedraza, S., et al. ( 2004 ) Plasma cellular‐fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 35, 1671 – 1676. | en_US |
dc.identifier.citedreference | van der Plas, R. M., Schiphorst, M. E., Huizinga, E. G., Hene, R. J., Verdonck, L. F., et al. ( 1999 ) von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation‐associated, thrombotic thrombocytopenic purpura. Blood 93, 3798 – 3802. | en_US |
dc.identifier.citedreference | Vincent, P. A., Rebres, R. A., Lewis, E. P., Hurst, V. t., and Saba, T. M. ( 1993 ) Release of ED1 fibronectin from matrix of perfused lungs after vascular injury is independent of protein synthesis. Am. J. Physiol. 265, L485 – 492. | en_US |
dc.identifier.citedreference | Kanters, S. D., Banga, J. D., Algra, A., Frijns, R. C., Beutler, J. J., and Fijnheer, R. ( 2001 ) Plasma levels of cellular fibronectin in diabetes. Diabetes Care 24, 323 – 327. | en_US |
dc.identifier.citedreference | Chauhan, A. K., Kisucka, J., Cozzi, M. R., Walsh, M. T., Moretti, F. A., et al. ( 2008 ) Prothrombotic effects of fibronectin isoforms containing the EDA domain. Arterioscler. Thromb. Vasc. Biol. 28, 296 – 301. | en_US |
dc.identifier.citedreference | Tomasini‐Johansson, B. and Mosher, D. F. ( 2009 ) Plasma fibronectin concentration in inbred mouse strains. Thromb. Haemost. 102, 1278 – 1280. | en_US |
dc.identifier.citedreference | Pecheniuk, N. M., Elias, D. J., Deguchi, H., Averell, P. M., and Griffin, J. H. ( 2008 ) Elevated plasma fibronectin levels associated with venous thromboembolism. Thromb. Haemost. 100, 224 – 228. | en_US |
dc.identifier.citedreference | Hynes, R. O. ( 2002 ) Integrins: bidirectional, allosteric signaling machines. Cell 110, 673 – 687. | en_US |
dc.identifier.citedreference | Chi‐Rosso, G., Gotwals, P. J., Yang, J., Ling, L., Jiang, K., et al. ( 1997 ) Fibronectin type III repeats mediate RGD‐independent adhesion and signaling through activated beta1 integrins. J. Biol. Chem. 272, 31447 – 31452. | en_US |
dc.identifier.citedreference | Korom, S., Hancock, W. W., Coito, A. J., and Kupiec‐Weglinski, J. W. ( 1998 ) Blockade of very late antigen‐4 integrin binding to fibronectin in allograft recipients. II. Treatment with connecting segment‐1 peptides prevents chronic rejection by attenuating arteriosclerotic development and suppressing intragraft T cell and macrophage activation. Transplantation 65, 854 – 859. | en_US |
dc.identifier.citedreference | Liao, Y. F., Gotwals, P. J., Koteliansky, V. E., Sheppard, D., and Van De Water, L. ( 2002 ) The EIIIA segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J. Biol. Chem. 277, 14467 – 14474. | en_US |
dc.identifier.citedreference | Amersi, F., Shen, X. D., Moore, C., Melinek, J., Busuttil, R. W., et al. ( 2003 ) Fibronectin‐alpha 4 beta 1 integrin‐mediated blockade protects genetically fat Zucker rat livers from ischemia/reperfusion injury. Am. J. Pathol. 162, 1229 – 1239. | en_US |
dc.identifier.citedreference | Johansson, S., Svineng, G., Wennerberg, K., Armulik, A., and Lohikangas, L. ( 1997 ) Fibronectin–integrin interactions. Front. Biosci. 2, d126 – d146. | en_US |
dc.identifier.citedreference | Petrovic, A., Alpdogan, O., Willis, L. M., Eng, J. M., Greenberg, A. S., et al. ( 2004 ) LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft‐versus‐host disease. Blood 103, 1542 – 1547. | en_US |
dc.identifier.citedreference | Kohan, M., Muro, A. F., White, E. S., and Berkman, N. ( 2010 ) EDA‐containing cellular fibronectin induces fibroblast differentiation through binding to {alpha}4{beta}7 integrin receptor and MAPK/Erk 1/2‐dependent signaling. FASEB J. 24, 4503 – 4512. | en_US |
dc.identifier.citedreference | Singh, P., Reimer, C. L., Peters, J. H., Stepp, M. A., Hynes, R. O., and Van De Water, L. ( 2004 ) The spatial and temporal expression patterns of integrin alpha9beta1 and one of its ligands, the EIIIA segment of fibronectin, in cutaneous wound healing. J. Invest. Dermatol. 123, 1176 – 1181. | en_US |
dc.identifier.citedreference | Okamura, Y., Watari, M., Jerud, E. S., Young, D. W., Ishizaka, S. T., et al. ( 2001 ) The extra domain A of fibronectin activates Toll‐like receptor 4. J. Biol. Chem. 276, 10229 – 10233. | en_US |
dc.identifier.citedreference | Hollestelle, S. C., De Vries, M. R., Van Keulen, J. K., Schoneveld, A. H., Vink, A., et al. ( 2004 ) Toll‐like receptor 4 is involved in outward arterial remodeling. Circulation 109, 393 – 398. | en_US |
dc.identifier.citedreference | Lasarte, J. J., Casares, N., Gorraiz, M., Hervas‐Stubbs, S., Arribillaga, L., et al. ( 2007 ) The extra domain A from fibronectin targets antigens to TLR4‐expressing cells and induces cytotoxic T cell responses in vivo. J. Immunol. 178, 748 – 756. | en_US |
dc.identifier.citedreference | Gondokaryono, S. P., Ushio, H., Niyonsaba, F., Hara, M., Takenaka, H., et al. ( 2007 ) The extra domain A of fibronectin stimulates murine mast cells via toll‐like receptor 4. J. Leukoc. Biol. 82, 657 – 665. | en_US |
dc.identifier.citedreference | Lefebvre, J. S., Levesque, T., Picard, S., Pare, G., Gravel, A., et al. ( 2011 ) The extra domain a of fibronectin primes leukotriene biosynthesis and stimulates neutrophil migration through toll‐like receptor 4 activation. Arthritis Rheum. | en_US |
dc.identifier.citedreference | Desmouliere, A., Chaponnier, C., and Gabbiani, G. ( 2005 ) Tissue repair,contraction, and the myofibroblast. Wound Repair Regen. 13, 7 – 12. | en_US |
dc.identifier.citedreference | Serini, G., Bochaton‐Piallat, M. L., Ropraz, P., Geinoz, A., Borsi, L., et al. ( 1998 ) The fibronectin domain ED‐A is crucial for myofibroblastic phenotype induction by transforming growth factor‐beta1. J. Cell Biol. 142, 873 – 881. | en_US |
dc.identifier.citedreference | Thannickal, V. J., Lee, D. Y., White, E. S., Cui, Z., Larios, J. M., et al. ( 2003 ) Myofibroblast differentiation by transforming growth factor‐beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. 278, 12384 – 12389. | en_US |
dc.identifier.citedreference | Ding, Q., Gladson, C. L., Wu, H., Hayasaka, H., and Olman, M. A. ( 2008 ) Focal adhesion kinase (FAK)‐related non‐kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK‐dependent manner. J. Biol. Chem. 283, 26839 – 26849. | en_US |
dc.identifier.citedreference | Greenberg, R. S., Bernstein, A. M., Benezra, M., Gelman, I. H., Taliana, L., and Masur, S. K. ( 2006 ) FAK‐dependent regulation of myofibroblast differentiation. FASEB J. 20, 1006 – 1008. | en_US |
dc.identifier.citedreference | White, E. S., Atrasz, R. G., Hu, B., Phan, S. H., Stambolic, V., et al. ( 2006 ) Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am. J. Respir. Crit. Care Med. 173, 112 – 121. | en_US |
dc.identifier.citedreference | Chan, M. W., Arora, P. D., Bozavikov, P., and McCulloch, C. A. ( 2009 ) FAK, PIP5KIgamma and gelsolin cooperatively mediate force‐induced expression of alpha‐smooth muscle actin. J. Cell Sci. 122, 2769 – 2781. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.